Please assess the completion status of the following clinical trial:

Trial Title: Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Age ≥ 18 years at time of informed consent~* Histologically- or cytologically-confirmed CRC that is metastatic~* Presence of BRAFV600E in tumor tissue as previously determined by a local assay at any time prior to Screening or by the central laboratory~* Progression of disease after 1 or 2 prior regimens in the metastatic setting~* Evidence of measurable or evaluable non-measurable disease per RECIST, v1.1~* Adequate bone marrow, cardiac, kidney and liver function~* Able to take oral medications~* Female patients are either postmenopausal for at least 1 year, are surgically sterile for at least 6 weeks, or must agree to take appropriate precautions to avoid pregnancy from screening through follow-up if of childbearing potential~* Males must agree to take appropriate precautions to avoid fathering a child from screening through follow-up~Key Exclusion Criteria:~* Prior treatment with any RAF inhibitor, MEK inhibitor, cetuximab, panitumumab or other epidermal growth factor receptor (EGFR) inhibitors~* Prior irinotecan hypersensitivity or toxicity that would suggest an inability to tolerate irinotecan 180 mg/m2 every 2 weeks~* Symptomatic brain metastasis or leptomeningeal disease~* History or current evidence of retinal vein occlusion or current risk factors for retinal vein occlusion (e.g., uncontrolled glaucoma or ocular hypertension, history of hyperviscosity or hypercoagulability syndromes)~* Known history of acute or chronic pancreatitis~* History of chronic inflammatory bowel disease or Crohn's disease requiring medical intervention (immunomodulatory or immunosuppressive medications or surgery) ≤12 months prior to randomization~* Uncontrolled blood pressure despite medical treatment~* Impaired GI function or disease that may significantly alter the absorption of encorafenib or binimetinib (e.g., ulcerative diseases, uncontrolled vomiting, malabsorption syndrome, small bowel resection with decreased intestinal absorption)~* Concurrent or previous other malignancy within 5 years of study entry, except cured basal or squamous cell skin cancer, superficial bladder cancer, prostate intraepithelial neoplasm, carcinoma in-situ of the cervix, or other noninvasive or indolent malignancy~* History of thromboembolic or cerebrovascular events ≤ 6 months prior to starting study treatment, including transient ischemic attacks, cerebrovascular accidents, deep vein thrombosis or pulmonary emboli~* Concurrent neuromuscular disorder that is associated with the potential of elevated creatine (phosphor)kinase (CK) (e.g., inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis, spinal muscular atrophy)~* Residual common terminology criteria for adverse events (CTCAE) ≥ Grade 2 toxicity from any prior anticancer therapy, with the exception of Grade 2 alopecia or Grade 2 neuropathy~* Known history of HIV infection~* Active hepatitis B or hepatitis C infection~* Known history of Gilbert's syndrome~* Known contraindication to receive cetuximab or irinotecan at the planned doses

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Safety Lead-in, Triplet Arm (Type: EXPERIMENTAL): Encorafenib + binimetinib + cetuximab.
- Doublet Arm (Type: EXPERIMENTAL): Encorafenib + cetuximab.
- Control Arm (Type: ACTIVE_COMPARATOR): Investigator's choice of either irinotecan/cetuximab or FOLFIRI/cetuximab.

Based on this trial design, predict the completion outcome and termination type (if applicable).